| Identification | Back Directory | [Name]
1α-(β-D-Glucopyranosyloxy)-1,4a,5,6,7,7aα-hexahydro-4aα-hydroxy-7α-methyl-5-oxocyclopenta[c]pyran-4-carboxylic acid methyl ester | [CAS]
50816-24-5 | [Synonyms]
Hastatoside
1α-(β-D-Glucopyranosyloxy)-1,4a,5,6,7,7aα-hexahydro-4aα-hydroxy-7α-methyl-5-oxocyclopenta[c]pyran-4-carboxylic acid methyl ester
Cyclopenta[c]pyran-4-carboxylic acid, 1-(β-D-glucopyranosyloxy)-1,4a,5,6,7,7a-hexahydro-4a-hydroxy-7-methyl-5-oxo-, methyl ester, (1S,4aR,7S,7aR)- | [Molecular Formula]
C17H24O11 | [MDL Number]
MFCD09752811 | [MOL File]
50816-24-5.mol | [Molecular Weight]
404.366 |
| Chemical Properties | Back Directory | [Boiling point ]
653.5±55.0 °C(Predicted) | [density ]
1.58±0.1 g/cm3 (20 ºC 760 Torr) | [storage temp. ]
-20°C | [form ]
Solid | [pka]
10.20±0.70(Predicted) | [color ]
White to off-white |
| Hazard Information | Back Directory | [Uses]
Hastatoside is an iridoid glucoside isolated found in Verbena officinalis and other herb plants. | [Definition]
ChEBI: Hastatoside is an iridoid monoterpenoid with formula C17H24O11 that is isolated from several plants including Verbena officinalis and exhibits a sleep-promoting effect. It has a role as a plant metabolite and a hepatoprotective agent. It is a beta-D-glucoside, an iridoid monoterpenoid, a cyclopentapyran, a monosaccharide derivative, a monoterpene glycoside, an alpha,beta-unsaturated carboxylic ester and a methyl ester. | [in vivo]
Hastatoside (0.32-0.64 mmol/kg; oral administration; for 9 hours; male rats of the Sprague-Dawley strain) treatment increases the total time of non-rapid eye movement sleep during a 9-h period, with a lag time of about 3-5 h after the administration at 20. 00 hours (lights-off time). Hastatoside also increases the delta activity during non-rapid eye movement sleep[1]. | Animal Model: | Male rats of the Sprague-Dawley strain (8 weeks old; 260-280 g)[1] | | Dosage: | 0.32 mmol/kg, 0.48 mmol/kg, 0.64 mmol/kg | | Administration: | Oral administration; for 9 hours | | Result: | Increased the total time of non-rapid eye movement sleep during a 9-h period, with a lag time of about 3-5 h after the administration at 20. 00 hours (lights-off time). Also increased the delta activity during non-rapid eye movement sleep.
|
|
|
|